1
|
Yang J, Su B, Liao R, Wang J, Bo S. Synthesis of pyrrolo[3,2-d]pyrimidineone derivatives as novel FXa inhibitors. Bioorg Med Chem Lett 2023; 80:129127. [PMID: 36634753 DOI: 10.1016/j.bmcl.2023.129127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2022] [Revised: 01/03/2023] [Accepted: 01/08/2023] [Indexed: 01/10/2023]
Abstract
A series of pyrrolo[3,2-d]pyrimidineone compounds have been designed and synthesized as novel FXa inhibitors. Bioassay of the tested compounds showed moderate to excellent anticoagulant potency in vitro. Further FXa inhibitory and bioactivity evaluation in rats, the FeCl3-induced venous thrombosis model, showed that the compound 17a has good FXa inhibitory activity (IC50 = 1.57 nM) and in vivo antithrombotic potency. The anticoagulant effects of compound 17a were dose dependent whether in vitro or in vivo. The results further confirmed our hypothesis that the large conjugated structure is an ideal skeleton binding FXa.
Collapse
Affiliation(s)
- Jiabin Yang
- Nanjing Zhongrui Pharmaceutical Co., Ltd, Nanjing, Jiangsu 211100, PR China
| | - Bolang Su
- Nanjing Zhongrui Pharmaceutical Co., Ltd, Nanjing, Jiangsu 211100, PR China
| | - Ruizhu Liao
- Nanjing Zhongrui Pharmaceutical Co., Ltd, Nanjing, Jiangsu 211100, PR China
| | - Jinrui Wang
- School of Medicine, Xuchang University, Xuchang, Henan 461000, PR China
| | - Shuyu Bo
- Department of Geriatrics, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, PR China.
| |
Collapse
|
2
|
Identification of new pyrazolyl piperidine molecules as factor Xa inhibitors: Design, synthesis, in silico, and biological evaluation. RESULTS IN CHEMISTRY 2022. [DOI: 10.1016/j.rechem.2022.100355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
3
|
Rodríguez DF, Durán-Osorio F, Duarte Y, Olivares P, Moglie Y, Dua K, Zacconi FC. Green by Design: Convergent Synthesis, Computational Analyses, and Activity Evaluation of New FXa Inhibitors Bearing Peptide Triazole Linking Units. Pharmaceutics 2021; 14:33. [PMID: 35056929 PMCID: PMC8780263 DOI: 10.3390/pharmaceutics14010033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 12/15/2021] [Accepted: 12/16/2021] [Indexed: 11/22/2022] Open
Abstract
Green chemistry implementation has led to promising results in waste reduction in the pharmaceutical industry. However, the early sustainable development of pharmaceutically active compounds and ingredients remains a considerable challenge. Herein, we wish to report a green synthesis of new pharmaceutically active peptide triazoles as potent factor Xa inhibitors, an important drug target associated with the treatment of diverse cardiovascular diseases. The new inhibitors were synthesized in three steps, featuring cycloaddition reactions (high atom economy), microwave-assisted organic synthesis (energy efficiency), and copper nanoparticle catalysis, thus featuring Earth-abundant metals. The molecules obtained showed FXa inhibition, with IC50-values as low as 17.2 μM and no associated cytotoxicity in HEK293 and HeLa cells. These results showcase the environmental potential and chemical implications of the applied methodologies for the development of new molecules with pharmacological potential.
Collapse
Affiliation(s)
- Diego F. Rodríguez
- Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile; (D.F.R.); (F.D.-O.)
| | - Francisca Durán-Osorio
- Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile; (D.F.R.); (F.D.-O.)
| | - Yorley Duarte
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago 8370035, Chile; (Y.D.); (P.O.)
| | - Pedro Olivares
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago 8370035, Chile; (Y.D.); (P.O.)
| | - Yanina Moglie
- Departamento de Química INQUISUR, Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca 8000, Argentina
| | - Kamal Dua
- Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia;
- Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia
| | - Flavia C. Zacconi
- Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile; (D.F.R.); (F.D.-O.)
- Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
- Centro de Investigaciones en Nanotecnología y Materiales Avanzados, CIEN-UC, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
| |
Collapse
|
4
|
Novel phenylalanine derived diamides as Factor XIa inhibitors. Bioorg Med Chem Lett 2016; 26:472-478. [DOI: 10.1016/j.bmcl.2015.11.089] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 11/20/2015] [Accepted: 11/24/2015] [Indexed: 12/30/2022]
|
5
|
Martiny VY, Martz F, Selwa E, Iorga BI. Blind Pose Prediction, Scoring, and Affinity Ranking of the CSAR 2014 Dataset. J Chem Inf Model 2015; 56:996-1003. [DOI: 10.1021/acs.jcim.5b00337] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Virginie Y. Martiny
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, LabEx LERMIT, 91198 Gif-sur-Yvette, France
- Department
of Nephrology and Dialysis, AP-HP, Tenon Hospital, INSERM UMR_S 1155, 75020 Paris, France
| | - François Martz
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, LabEx LERMIT, 91198 Gif-sur-Yvette, France
| | - Edithe Selwa
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, LabEx LERMIT, 91198 Gif-sur-Yvette, France
| | - Bogdan I. Iorga
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, LabEx LERMIT, 91198 Gif-sur-Yvette, France
| |
Collapse
|
6
|
|
7
|
Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov 2015; 14:183-202. [DOI: 10.1038/nrd4534] [Citation(s) in RCA: 166] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
8
|
Shi ZH, Li NG, Tang YP, Duan JA. Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245. Expert Opin Ther Pat 2014; 24:1139-48. [PMID: 25231888 DOI: 10.1517/13543776.2014.959493] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Thrombotic disorders can lead to deep vein thrombosis, myocardial infarction and stroke. Thrombin plays a vital role in cascade reaction of blood coagulation, inhibition of the activity of thrombin can block the formation of thrombus and direct thrombin inhibitor has a prospect to overcome the limitations in application of the traditional anticoagulant drugs. AREAS COVERED The current patent US2013296245 describes a series of prolinamide derivatives with formula (I) as thrombin inhibitors. These new compounds are defined to be pharmaceutically acceptable salts derived from pharmaceutically acceptable inorganic acid and organic acid, and pharmaceutically acceptable prodrug where N-alkoxycarbonyl is protected or carboxylic acid is protected by ester. EXPERT OPINION The patent used formamidine and its N-alkoxycarbonyl-protected derivatives as the P1 group; these groups were less basic compared with the traditional guanidine group, so their lipophilicity could be optimized to achieve oral absorption. Furthermore, these pharmaceutically acceptable prodrugs where N-alkoxycarbonyl is protected or carboxylic acid is protected by ester could achieve prolonged half-life for a convenient once- or twice-daily oral dosing. These efforts gave a new hope and confidence to treat thrombotic disorders with selective and orally active thrombin inhibitors.
Collapse
Affiliation(s)
- Zhi-Hao Shi
- Nanjing University of Chinese Medicine, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine , 138 Xianlin Road, Nanjing 210023, Jiangsu , PR China +86 25 85811916 ; +86 25 85811916 ; ,
| | | | | | | |
Collapse
|
9
|
LC–MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis 2014; 6:2071-82. [DOI: 10.4155/bio.14.66] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Background: apixaban (BMS-562247) (Eliquis®) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. Methodology/results: A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC–MS/MS. Run times were approximately 3 min. The lower limit of quantification (LLOQ) was 1.00 ng/ml for BMS-562247 and 5.00 ng/ml for BMS-730823. Intra- and inter-assay precision values for replicate QC control samples were within ≤5.36% for both analytes (≤7.52% at the LLOQ). The accuracy for both analytes was within ±9.00%. Conclusion: The method was demonstrated to be sensitive, selective and robust, and was successfully used to support clinical studies.
Collapse
|
10
|
Orwat MJ, Qiao JX, He K, Rendina AR, Luettgen JM, Rossi KA, Xin B, Knabb RM, Wexler RR, Lam PY, Pinto DJ. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties. Bioorg Med Chem Lett 2014; 24:3341-5. [DOI: 10.1016/j.bmcl.2014.05.101] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2014] [Revised: 05/27/2014] [Accepted: 05/29/2014] [Indexed: 02/06/2023]
|
11
|
|
12
|
Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther 2013; 11:129-141. [DOI: 10.1586/erc.12.172] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
|
13
|
Current world literature. Curr Opin Cardiol 2012. [PMID: 23207493 DOI: 10.1097/hco.0b013e32835c1388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|